SEC Form 4 · accession 0001842190-26-000011
Tarsus Pharmaceuticals, Inc. · TARS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elizabeth Yeu Lin
Officer — Chief Medical Officer
Period of report
Sep 4, 2026
Accepted (ET)
Sep 9, 2026 · 4:13 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001819790
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 4, 2026 | S | 5,387 | $85.00 | D | 7,933 | D | |
| Common Stock | Sep 4, 2026 | S | 5,386 | $90.00 | D | 2,547 | D | |
| Common Stock | Sep 4, 2026 | S | 1,590 | $85.00 | D | 3,180 | I | By Spouse's Roth IRA |
| Common Stock | Sep 4, 2026 | S | 1,590 | $90.00 | D | 1,590 | I | By Spouse's Roth IRA |
| Common Stock | holding | — | — | — | 12,040 | I | By 401(k) Plan |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.
- F2The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026.